Verapamil bioavailability and dosage in liver disease.
作者信息
Woodcock B G, Rietbrock N
出版信息
Br J Clin Pharmacol. 1982 Feb;13(2):240-1. doi: 10.1111/j.1365-2125.1982.tb01367.x.
Abstract
摘要
相似文献
1
Verapamil bioavailability and dosage in liver disease.维拉帕米在肝脏疾病中的生物利用度及剂量
Br J Clin Pharmacol. 1982 Feb;13(2):240-1. doi: 10.1111/j.1365-2125.1982.tb01367.x.
2
Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.肝硬化患者维拉帕米的药代动力学、生物利用度及心电图反应
Br J Clin Pharmacol. 1981 Jul;12(1):51-60. doi: 10.1111/j.1365-2125.1981.tb01854.x.
3
[Drugs with first-pass elimination. Verapamil and dihydroergotamine alkaloids].[具有首过消除效应的药物。维拉帕米和二氢麦角胺生物碱]
Internist (Berl). 1982 Nov;23(11):610-5.
4
Effects of liver fibrosis on verapamil pharmacokinetics in rats.肝纤维化对大鼠维拉帕米药代动力学的影响。
Clin Exp Pharmacol Physiol. 2008 Mar;35(3):287-94. doi: 10.1111/j.1440-1681.2007.04826.x. Epub 2007 Oct 31.
5
The bioavailability of a slow-release verapamil formulation.一种缓释维拉帕米制剂的生物利用度。
Br J Clin Pract Suppl. 1985 Jun;42:9-16.
6
7
Clinical pharmacokinetics of verapamil.维拉帕米的临床药代动力学
Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002.
8
Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.
Clin Pharmacol Ther. 1981 Jan;29(1):27-34. doi: 10.1038/clpt.1981.5.
9
[Drug metabolism in patients with liver disease (author's transl)].肝病患者的药物代谢（作者译）
Leber Magen Darm. 1980 Oct;10(5):234-40.
10
Physiological disposition of verapamil in man.维拉帕米在人体中的生理分布。
Cardiovasc Res. 1976 Sep;10(5):605-12. doi: 10.1093/cvr/10.5.605.
引用本文的文献
1
Management of calcium channel antagonist overdose.钙通道拮抗剂过量的处理
Drug Saf. 2003;26(2):65-79. doi: 10.2165/00002018-200326020-00001.
本文引用的文献
1
Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.
Clin Pharmacol Ther. 1981 Jan;29(1):27-34. doi: 10.1038/clpt.1981.5.
2
Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.肝硬化患者维拉帕米的药代动力学、生物利用度及心电图反应
Br J Clin Pharmacol. 1981 Jul;12(1):51-60. doi: 10.1111/j.1365-2125.1981.tb01854.x.
3
Verapamil and norverapamil plasma concentrations during long-term therapy in patients with hypertrophic obstructive cardiomyopathy.肥厚性梗阻性心肌病患者长期治疗期间维拉帕米和去甲维拉帕米的血浆浓度。
J Cardiovasc Pharmacol. 1980 Jan-Feb;2(1):17-23. doi: 10.1097/00005344-198001000-00003.
4
Commentary: a physiological approach to hepatic drug clearance.述评：肝脏药物清除的生理学方法
Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377.
5
Physiological disposition of verapamil in man.维拉帕米在人体中的生理分布。
Cardiovasc Res. 1976 Sep;10(5):605-12. doi: 10.1093/cvr/10.5.605.
Zotero 插件